EP4061386A4 - Verfahren zur herstellung von multivirusspezifischen t-zellen - Google Patents

Verfahren zur herstellung von multivirusspezifischen t-zellen

Info

Publication number
EP4061386A4
EP4061386A4 EP19928301.1A EP19928301A EP4061386A4 EP 4061386 A4 EP4061386 A4 EP 4061386A4 EP 19928301 A EP19928301 A EP 19928301A EP 4061386 A4 EP4061386 A4 EP 4061386A4
Authority
EP
European Patent Office
Prior art keywords
multivirus
cells
producing
specific
producing multivirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19928301.1A
Other languages
English (en)
French (fr)
Other versions
EP4061386A1 (de
Inventor
Ercüment Ovali
Gözde Karaku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acibadem Labmed Saglik Hizmetleri AS
Original Assignee
Acibadem Labmed Saglik Hizmetleri AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acibadem Labmed Saglik Hizmetleri AS filed Critical Acibadem Labmed Saglik Hizmetleri AS
Publication of EP4061386A1 publication Critical patent/EP4061386A1/de
Publication of EP4061386A4 publication Critical patent/EP4061386A4/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/22011—Polyomaviridae, e.g. polyoma, SV40, JC
    • C12N2710/22034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP19928301.1A 2019-11-19 2019-12-13 Verfahren zur herstellung von multivirusspezifischen t-zellen Pending EP4061386A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201918044 2019-11-19
PCT/TR2019/051071 WO2021101466A1 (en) 2019-11-19 2019-12-13 A method for producing multivirus specific t cells

Publications (2)

Publication Number Publication Date
EP4061386A1 EP4061386A1 (de) 2022-09-28
EP4061386A4 true EP4061386A4 (de) 2024-01-10

Family

ID=75980745

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19928301.1A Pending EP4061386A4 (de) 2019-11-19 2019-12-13 Verfahren zur herstellung von multivirusspezifischen t-zellen

Country Status (2)

Country Link
EP (1) EP4061386A4 (de)
WO (1) WO2021101466A1 (de)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (en) * 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2018052947A1 (en) * 2016-09-16 2018-03-22 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013119947A1 (en) * 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
WO2018052947A1 (en) * 2016-09-16 2018-03-22 Baylor College Of Medicine Platform for activation and expansion of virus-specific t-cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
NISHIYAMA-FUJITA YURIKO ET AL: "Generation of multivirus-specific T cells by a single stimulation of peripheral blood mononuclear cells with a peptide mixture using serum-free medium", CYTOTHERAPY, vol. 20, no. 9, 1 September 2018 (2018-09-01), GB, pages 1182 - 1190, XP093101449, ISSN: 1465-3249, DOI: 10.1016/j.jcyt.2018.05.009 *
OMER BILAL ET AL: "Administration of Most Closely HLA-Matched Multivirus-Specific T Cells for the Treatment of EBV, CMV, AdV, HHV6, and BKV Post Allogeneic Hematopoietic Stem Cell Transplant", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, vol. 126, no. 23, 3 December 2015 (2015-12-03), pages 622, XP086642640, ISSN: 0006-4971, DOI: 10.1182/BLOOD.V126.23.622.622 *
P. J. HANLEY ET AL: "Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes", BLOOD, vol. 114, no. 9, 27 August 2009 (2009-08-27), pages 1958 - 1967, XP055200362, ISSN: 0006-4971, DOI: 10.1182/blood-2009-03-213256 *
See also references of WO2021101466A1 *
ULRIKE GERDEMANN ET AL: "Rapidly Generated Multivirus-specific Cytotoxic T Lymphocytes for the Prophylaxis and Treatment of Viral Infections", MOLECULAR THERAPY, 17 July 2012 (2012-07-17), XP055034394, ISSN: 1525-0016, DOI: 10.1038/mt.2012.130 *
VIJAYENDRA DASARI ET AL: "Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients", MOLECULAR THERAPY- METHODS & CLINICAL DEVELOPMENT, vol. 3, 1 January 2016 (2016-01-01), GB, pages 1 - 9, XP055465882, ISSN: 2329-0501, DOI: 10.1038/mtm.2016.58 *

Also Published As

Publication number Publication date
WO2021101466A1 (en) 2021-05-27
EP4061386A1 (de) 2022-09-28

Similar Documents

Publication Publication Date Title
IL276597A (en) A method for producing a low antigenic cell
EP3747996A4 (de) Verfahren zur herstellung von zellen
IL280041A (en) A method for producing gamma delta T cells
IL280323A (en) A method for preparing a cd3-positive cell
IL280556A (en) Cell production method
IL291531A (en) A method for activating a cell
EP4032851A4 (de) Verfahren zur herstellung eines feststoffelektrolyten
HUE062863T2 (hu) Eljárás szulfid szilárd elektrolit elõállítására
EP3842522A4 (de) Verfahren zur herstellung von regulatorischen t-zellen
EP4053267A4 (de) Verfahren zur herstellung von t-zellen
IL287063A (en) A method for producing a similar structure-biotissue
SG11202113036WA (en) Process for producing a binder
IL274330A (en) A process for producing a T-cell compound
EP3950942A4 (de) Verfahren zur herstellung einer knock-in zelle
EP3882347A4 (de) Verfahren zur herstellung von genomeditierten zellen
IL287948A (en) A method for preparing a biocide
EP4004165C0 (de) Methode zur herstellung einer brennstofftablette
EP3993976C0 (de) Verfahren zur herstellung eines konstruktionselements
EP4061386A4 (de) Verfahren zur herstellung von multivirusspezifischen t-zellen
EP3896155A4 (de) Herstellungsverfahren für genomeditierte zellen
SG11202111060VA (en) Method for producing perfluoroalkyne compound
LT3459531T (lt) Sluoksniuotos tabletės gamybos būdas
GB2589201B (en) Method for producing a water-hydraulic machine
EP4084019A4 (de) Verfahren zur herstellung eines feststoffelektrolyten
GB201818045D0 (en) Method for producing erythroid cells

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211021

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20231212

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101ALI20231206BHEP

Ipc: C12N 5/00 20060101ALI20231206BHEP

Ipc: A61K 35/17 20150101AFI20231206BHEP